MGFA has partnered with Bionews to feature the Myasthenia Gravis News feed on our myasthenia.org website. We are excited to offer the MG Community this insightful and informative news feed that covers many aspects of living with myasthenia – from research and study results to managing MG, helpful tips, and important news from across the MG World.
Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- Titin antibody, hospitalizations linked in non-thymoma MGby Andrea Lobo on December 3, 2024 at 1:00 pm
The presence of antibodies targeting titin, a type of muscle protein, in patients with myasthenia gravis (MG) not associated with a thymus tumor is related to more frequent hospitalizations, according The post Titin antibody, hospitalizations linked in non-thymoma MG appeared first on Myasthenia Gravis News.
- My twin often considers the worst-case scenario in his life with MGby Allen Francis on November 29, 2024 at 3:00 pm
American writer William Arthur Ward is believed to have said, “Feeling gratitude and not expressing it is like wrapping a gift and not giving it.” I’m not grateful enough for The post My twin often considers the worst-case scenario in his life with MG appeared first on Myasthenia Gravis News.
- Soliris, Ultomiris ‘promising’ as long-term treatments for MG: Reportby Patricia Inacio, PhD on November 29, 2024 at 1:00 pm
A man with a 16-year history of hard-to-treat generalized myasthenia gravis finally saw his disease successfully managed with Soliris (eculizumab) and then with Ultomiris (ravulizumab) — highlighting the efficacy of these The post Soliris, Ultomiris ‘promising’ as long-term treatments for MG: Report appeared first on Myasthenia Gravis News.
- How I’m facing my fears in life with a rare diseaseby Sarah Bendiff on November 28, 2024 at 3:00 pm
Last year, I woke up to terrible news: One of my colleagues had passed away. Although I didn’t know her personally, I knew she’d lived with a chronic illness and The post How I’m facing my fears in life with a rare disease appeared first on Myasthenia Gravis News.
- Vyvgart a rapid, effective treatment for impending myasthenic crisisby Andrea Lobo on November 27, 2024 at 1:00 pm
Treatment with Vyvgart (efgartigimod) may rapidly and safely ease symptoms during an impending myasthenic crisis in people with myasthenia gravis (MG), according to a study in China. Impending myasthenic crisis, The post Vyvgart a rapid, effective treatment for impending myasthenic crisis appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.